DRKS00026238
Completed
Not Applicable
Pilotstudy about the role of regulatory immune cells in autoimmunity, cancer and organ rejection after kidney transplantation - /
Medizinische Universität Graz, Department für Innere Medizin, Abteilung für Endokrinologie und Diabetologie0 sites485 target enrollmentSeptember 27, 2021
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- E10
- Sponsor
- Medizinische Universität Graz, Department für Innere Medizin, Abteilung für Endokrinologie und Diabetologie
- Enrollment
- 485
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Group 1: Healthy participants: healthy participants with no history of autoimmune diseases, transplantation or cancer diseases / Group 2: Type 1 Diabetes Mellitus patients: Manifested type 1 diabetes mellitus as defined by treating physicians / Group 3: Rheumatoid Arthritis patients: Manifested rheumatoid arthritis as defined by 2010 ACR/EUCLAR criteria / Group 4: Systemic Lupus erythematodes patients: Manifested systemic lupus erythematodes as defined by the 2012 SLICC crietria / Group 5: Systemic sclerosis patients: Manifested systemic slcerosis as defined by the EULAR/ACR 2013 classification criteria / Group 6: Cancer patients: Histologically confirmed colo\-rectal cancer / Group 7: Kidney transplant recipients: Patients who received a first kidney transplantation
Exclusion Criteria
- •Exclusion criteria for all patients involved in this study: pregnancy; acute or chronic infection / Exclusion criteria per defined study\-subgroup:
- •Group 1: Healthy participants: any history of autoimmune diseases, transplantation or cancer diseases; glucocorticoid or immunosuppressive therapy within the last 3 months; manifest Type 2 diabetes mellitus / Group 2: Type 1 Diabetes Mellitus patients: glucocorticoid or immunosuppressive therapy within the last 3 months; neoplastic diseases / Group 3: Rheumatoid Arthritis patients: neoplastic diseases / Group 4: Systemic Lupus erythematodes patients: neoplastic diseases / Group 5: Systemic sclerosis patients: neoplastic diseases / Group 6: Cancer patients: ongoing chemotherapy; ongoing immunotherapy; ongoing therapy with biologicals; existence of an auto\-immune disease; manifest type 2 diabetes mellitus disease / Group 7: Kidney transplant recipients: patients receiving a second, third or fourth kidney transplant; glucocorticoid or immunosuppressive therapy within the lat 3 months, AB0\-incompative kidney transplantation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Study for the regulation mechanism of body immune function by meditatioITMCTR1900002782Beijing University of Chinese Medicine
Active, not recruiting
Phase 1
PILOT STUDY TO ASSESS THE ROLE OF IMMUNE ACTIVATION AND APOPTOSIS AS A MARKER FOR TREATMENT INTENSIFICATION WITH RALTEGRAVIR IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY WITH LONG-TERM VIRAL SUPPRESSION AND UNFAVOURABLE IMMUNOLOGIC RESPONSE (DISCORDANT PATIENTS: V+I-).Infección VIH-1MedDRA version: 9Level: LLTClassification code 10008919Term: Chronic HIV infectionEUCTR2008-005473-35-ESFundació Lluita contra la SIDA44
Recruiting
Not Applicable
A pilot study to investigate the immunological regulation of preeclampsiaO14Pre-eclampsiaDRKS00025864Carl von Ossietzky Universität Oldenburg/Klinikum Oldenburg; Universitätsklinik für Gynäkologie und Geburtshilfe200
Completed
Not Applicable
Expression of immune-related signal regulatory protein on peripheral blood mononuclear cells in non-small cell lung cancer patientsnon-small cell lung cancerblood screeninglung cancerPBMCTCTR20190508003/A60
Recruiting
Not Applicable
Study on the importance of cellular immune response in malignant tumors, autoimmune diseases, immunodeficiency syndromes, after organ transplantation and during pregnancyCancer, Autoimmune Diseases, Immune Deficiency Syndromes, PregnancyDRKS00008016niversitätsklinikum Köln1,000